ARCHIVES

Orlando Health President Mark Rohl We Opted For A Florida-Centric Strategy

This article is from The Cancer Letter archive.

Vol. 40 No. 02 | January 10, 2014

Download PDF Visit The Full Archive

Related Articles

Ungerleider To Leave NCI For Theradex Corp.

November 24, 2000

ODAC Endorses Tamoxifen Trial, With Modification to Ensure Enrollment of Women At Higher Risk

August 2, 1991

ACS To open Key Positions To Competition In Massive “Reorganization for the ‘90’s

August 6, 1993

Two New Communications Contracts Approved

October 18, 1985

Herceptin Recommended As Adjuvant For HER2 Positive Early Breast Cancer

May 27, 2005

Grassley, House Republicans Launch Investigations Of I-ELCAP Conflicts.

June 6, 2008